PURPOSE: The elimination half-life and consequently the accumulation of enoxaparin increase as glomerular filtration rate (GFR) decreases. A dose adjustment for patients with a GFR <30 ml/min is recommended and considered relatively safe. Our intention was to identify whether the use of enoxaparin is safe and to determine what impact an enoxaparin dose adjustment has on patients with a GFR <60 ml/min. METHODS: A PubMed search and meta-analysis of literature were performed. Studies were analyzed to compare enoxaparin versus other heparins/heparinoids and investigate enoxaparin at different stages of kidney dysfunction. Only controlled trials were considered, and the enoxaparin dose had to be specified. The clinical endpoint was defined as apparent major bleeding. RESULTS: Out of 1,027 publications, 20 studies met the criteria and were analyzed. Our meta-analysis shows that enoxaparin major bleeding complications at a GFR < 60 ml/min increase significantly, with a relative risk (RR) of 1.67 [95% confidence interval (CI) 1.12-2.50) compared with other anticoagulants (p = 0.01). RR for patients on enoxaparin therapy increases exponentially with each stage of chronic kidney disease (CKD stage 1-5) [RR = 0.585 x exp(0.524 x CKD)]. Despite dose adjustment, the major bleeding risk is still significantly increased in patients with a GFR < 60 ml/min versus those with a GFR > 60 ml/min. CONCLUSION: Only patients with a GFR > 60 ml/min can be safely treated with enoxaparin.
PURPOSE: The elimination half-life and consequently the accumulation of enoxaparin increase as glomerular filtration rate (GFR) decreases. A dose adjustment for patients with a GFR <30 ml/min is recommended and considered relatively safe. Our intention was to identify whether the use of enoxaparin is safe and to determine what impact an enoxaparin dose adjustment has on patients with a GFR <60 ml/min. METHODS: A PubMed search and meta-analysis of literature were performed. Studies were analyzed to compare enoxaparin versus other heparins/heparinoids and investigate enoxaparin at different stages of kidney dysfunction. Only controlled trials were considered, and the enoxaparin dose had to be specified. The clinical endpoint was defined as apparent major bleeding. RESULTS: Out of 1,027 publications, 20 studies met the criteria and were analyzed. Our meta-analysis shows that enoxaparin major bleeding complications at a GFR < 60 ml/min increase significantly, with a relative risk (RR) of 1.67 [95% confidence interval (CI) 1.12-2.50) compared with other anticoagulants (p = 0.01). RR for patients on enoxaparin therapy increases exponentially with each stage of chronic kidney disease (CKD stage 1-5) [RR = 0.585 x exp(0.524 x CKD)]. Despite dose adjustment, the major bleeding risk is still significantly increased in patients with a GFR < 60 ml/min versus those with a GFR > 60 ml/min. CONCLUSION: Only patients with a GFR > 60 ml/min can be safely treated with enoxaparin.
Authors: Jean-Philippe Collet; Gilles Montalescot; Giancarlo Agnelli; Frans Van de Werf; Enrique P Gurfinkel; Jose López-Sendón; Christopher V Laufenberg; Martin Klutman; Neelam Gowda; Dietrich Gulba Journal: Eur Heart J Date: 2005-06-02 Impact factor: 29.983
Authors: Sarah A Spinler; Kenneth W Mahaffey; Dianne Gallup; Glenn N Levine; James J Ferguson; Sunil V Rao; Richard Gallo; John Ducas; Shaun G Goodman; Elliott Antman; Harvey D White; Luigi Biasucci; Richard C Becker; Jacques J Col; Marc Cohen; Robert A Harrington; Robert M Califf Journal: Int J Cardiol Date: 2009-05-05 Impact factor: 4.164
Authors: Keith A A Fox; Elliott M Antman; Gilles Montalescot; Stefan Agewall; Bhupathi SomaRaju; Freek W A Verheugt; Jose Lopez-Sendon; Hanoch Hod; Sabina A Murphy; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2007-05-25 Impact factor: 24.094
Authors: J P Fillastre; A Leroy; C Baudoin; G Humbert; E A Swabb; C Vertucci; M Godin Journal: Clin Pharmacokinet Date: 1985 Jan-Feb Impact factor: 6.447
Authors: J C Easaw; M A Shea-Budgell; C M J Wu; P M Czaykowski; J Kassis; B Kuehl; H J Lim; M MacNeil; D Martinusen; P A McFarlane; E Meek; O Moodley; S Shivakumar; V Tagalakis; S Welch; P Kavan Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677
Authors: M Carrier; A Lazo-Langner; S Shivakumar; V Tagalakis; P L Gross; N Blais; C A Butts; M Crowther Journal: Curr Oncol Date: 2015-02 Impact factor: 3.677
Authors: Reza Mehrazin; Zachary Piotrowski; Brian Egleston; Daniel Parker; Jeffrey J Tomaszweski; Marc C Smaldone; Philip H Abbosh; Timothy Ito; Paul Bloch; Kevan Iffrig; Marijo Bilusic; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Robert G Uzzo; Alexander Kutikov Journal: Urology Date: 2014-10-24 Impact factor: 2.649
Authors: Andrew Frazer; James Rowland; Alison Mudge; Michael Barras; Jennifer Martin; Peter Donovan Journal: Eur J Clin Pharmacol Date: 2019-09-11 Impact factor: 2.953